Molecular iodine exerts antineoplastic effects by diminishing proliferation and invasive potential and activating the immune response in mammary cancer xenografts
Open Access
- 22 March 2019
- journal article
- research article
- Published by Springer Science and Business Media LLC in BMC Cancer
- Vol. 19 (1), 1-12
- https://doi.org/10.1186/s12885-019-5437-3
Abstract
The immune system is a crucial component in cancer progression or regression. Molecular iodine (I2) exerts significant antineoplastic effects, acting as a differentiation inductor and immune modulator, but its effects in antitumor immune response are not elucidated. The present work analyzed the effect of I2 in human breast cancer cell lines with low (MCF-7) and high (MDA-MB231) metastatic potential under both in vitro (cell proliferation and invasion assay) and in vivo (xenografts of athymic nude mice) conditions. In vitro analysis showed that the 200 μM I2 supplement decreases the proliferation rate in both cell lines and diminishes the epithelial-mesenchymal transition (EMT) profile and the invasive capacity in MDA-MB231. In immunosuppressed mice, the I2 supplement impairs implantation (incidence), tumoral growth, and proliferation of both types of cells. Xenografts of the animals treated with I2 decrease the expression of invasion markers like CD44, vimentin, urokinase plasminogen activator and its receptor, and vascular endothelial growth factor; and increase peroxisome proliferator-activated receptor gamma. Moreover, in mice with xenografts, the I2 supplement increases the circulating level of leukocytes and the number of intratumoral infiltrating lymphocytes, some of them activated as CD8+, suggesting the activation of antitumor immune responses. I2 decreases the invasive potential of a triple negative basal cancer cell line, and under in vivo conditions the oral supplement of this halogen activates the antitumor immune response, preventing progression of xenografts from laminal and basal mammary cancer cells. These effects allow us to propose iodine supplementation as a possible adjuvant in breast cancer therapy.Keywords
Funding Information
- PAPIIT-UNAM (201516, 209717)
- CONACyT (176911, 235961)
This publication has 38 references indexed in Scilit:
- The Extrathyronine Actions of Iodine as Antioxidant, Apoptotic, and Differentiation Factor in Various TissuesThyroid®, 2013
- CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activityBreast Cancer Research, 2012
- Uptake and antitumoral effects of iodine and 6‐iodolactone in differentiated and undifferentiated human prostate cancer cell linesThe Prostate, 2012
- Definition and classification of cancer cachexia: an international consensusThe Lancet Oncology, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Matrix Metalloproteinases: Regulators of the Tumor MicroenvironmentCell, 2010
- Immunity, Inflammation, and CancerCell, 2010
- IL-4 induces cathepsin protease activity in tumor-associated macrophages to promote cancer growth and invasionGenes & Development, 2010
- A complex between 6-iodolactone and the peroxisome proliferator-activated receptor type gamma may mediate the antineoplasic effect of iodine in mammary cancerProstaglandins & Other Lipid Mediators, 2009
- Antibody treatment of human tumor xenografts elicits active anti-tumor immunity in nude miceImmunology Letters, 2007